Detalhe da pesquisa
1.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 339-351, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30795951
2.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet
; 386(9992): 433-43, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26040499
3.
Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Int J Gynecol Cancer
; 25(2): 257-62, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25611899
4.
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Wien Med Wochenschr
; 165(19-20): 387-94, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26471371
5.
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
Int J Gynecol Cancer
; 23(1): 73-80, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23211422
6.
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
J Clin Oncol
; 38(32): 3753-3762, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822286
7.
Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Chemotherapy
; 55(6): 391-8, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19955744
8.
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Expert Rev Anticancer Ther
; 18(sup1): 19-22, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30223697
9.
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Eur J Cancer
; 70: 111-121, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27914241
10.
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Expert Rev Anticancer Ther
; 16(sup1): 11-19, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27797622
11.
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
Wien Klin Wochenschr
; 122(21-22): 649-52, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21072604